

Extracorporeal **Shockwave Therapy** Versus Placebo for the Treatment of Chronic Proximal Plantar Fasciitis: Results of a Randomized, Placebo-Controlled, Double-Blinded, Multicenter Intervention Trial.[Article]

Author:

Malay, D. Scot DPM, MSCE 1; Pressman, Martin M. DPM 2; Assili, Amir DPM 3; Kline, Jason T. DPM 4; York, Shane DPM 5; Buren, Ben DPM 6; Heyman, Eugene R. PhD 7; Borowsky, Pam DPM, CPed 8; LeMay, Carley MA 9

Institution

(1)Ankle and Foot Medical Centers of the Delaware Valley, Penn-Presbyterian Medical Center, Postdoctoral Research Fellow, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA.

(2)Chief, Section of Podiatric Surgery, Yale-New Haven Hospital, Clinical Assistant Professor, Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven Foot Surgeons, New Haven, CT.

(3)Podiatric Director, Shady Grove Wound Center, Shady Grove Podiatry, Gaithersburg, MD.

(4)Chief Resident, Penn-Presbyterian Medical Center, Philadelphia, PA.

(5)Chief Resident, Podiatric Surgery, Yale-New Haven Hospital, New Haven, CT.

(6)Chief Resident, Podiatric Surgery, Yale-New Haven Hospital, New Haven, CT.

(7)Statistical Consultant, Montgomery Village, MD.

(8)Ankle and Foot Medical Centers of the Delaware Valley, Philadelphia, PA.

(9)Shady Grove Podiatry, Gaithersburg, MD.

Extracorporeal **shockwave therapy** (ESWT) has demonstrated efficacy in the treatment of recalcitrant proximal plantar fasciitis. The objective of this investigation was to compare the outcomes of participants treated with a new ESWT device with those treated with placebo. A total of 172 volunteer participants were randomized in a 2:1 active-to-placebo ratio in this prospective, double-blind, multicenter trial conducted between October 2003 and December 2004. ESWT (n = 115) or placebo control (n = 57) was administered on a single occasion without local or systemic anesthesia or sedation, after which follow-up was undertaken. The primary outcomes were the blind assessor's objective, and the participant's subjective assessments of heel pain during the first 3 months of follow-up. Participants were also followed up to 1 year to identify any adverse outcomes that may have been related to the **shockwave** device. On the visual analog scale, the blind assessor's objective assessment of heel pain displayed a mean reduction of 2.51 in the **shockwave** group and 1.57 in the placebo group; this difference was statistically significant (P = .045). On the visual analog scale, the participant's self-assessment of heel pain displayed a mean reduction of 3.39 in the **shockwave** group and 1.78 in the placebo group; this difference was statistically significant (P < .001). No serious adverse events were observed at any time. It was concluded that ESWT was both efficacious and safe for participants with chronic proximal plantar fasciitis that had been unresponsive to exhaustive conservative treatment.